聚甲基丙烯酸-对-甲氧基偶氮苯烷氧基酯的合成及柔性间隔基对液晶行为的影响

通过甲基丙烯酸钾盐与溴化物的反应合成了一系列柔性间隔基长度不同的甲基丙烯酸 对 甲氧基偶氮苯烷氧基酯（ＰＭＡＡＺＯｎ,ｎ＝２,３,４,５,６）,然后聚合成相应的聚合物．用１Ｈ ＮＭＲ和ＩＲ表征了聚合物的结构,ＧＰＣ测定了分子量,ＤＳＣ和偏光显微镜观测了液晶高分子的相行为和织构．研究了间隔基长度对织构、相变和热力学性质的影响,观测到聚合物的ＴＮＩ随间隔基的长度变化表现出的奇偶效应．     

3-[P-(P-(P-甲氧基苯乙炔基)苯乙炔基)苯氧基]丙烯酸丙酯合成与表征

以对甲氧基苯乙炔、对溴苯酚、3-氯-1-丙醇和甲基丁炔醇等为原料,通过williamson反应、Sonogashina和酯化等反应合成3[P-(P-(P-甲氧基苯乙炔基)苯乙炔基)苯氧基]丙烯酸丙酯.用元素分析,IR和1HNMR等手段对产物的组成和结构进行了表征,并讨论反应物量、催化剂等因素对产率的影响.     

N-[4-(三氟甲氧基)苯基]氨基甲酸苯酯的合成

以三氟甲氧基苯为起始原料,经硝化、加氢还原和酰化反应合成了N-[4-(三氟甲氧基)苯基]氨基甲酸苯酯,总收率84.6%,纯度98.9%,其结构经¹H NMR和MS（ESI）确证。     

电化学合成1, 4-双[2-(3, 4, 5-三甲氧基苯基)乙烯基]苯

1,4-双[2-(3,4,5-三甲氧基苯基]苯[简称HPV]采用有机电化学的方法合成,对合成的原理和方法进行研究和探讨,得到此化合物的三种异构体的淡黄色混合物,即含29.4%全顺式,44.7%顺-反式和25.9%全顺式。所得混合物熔点范围为103-155℃,总得率为92%。     

光致变色液晶高分子研究(Ⅳ)─含苯甲酸－4－甲氧基苯酯介晶基元和偶氮苯光色基元侧链共聚硅氧烷的液晶行为

用热台偏光显微镜和DSC法研究了含苯甲酸-4-甲氧基苯酯介晶基元和偶氮苯光色基元侧链共聚硅氧烷(PSⅡ)的液晶性。将非介晶基元并入液晶均聚物PSⅡ-1,共聚物PSⅡ-2、PSⅡ-3的液晶态类型不变,PSⅡ-4仅存在近晶相,PSⅡ-5～8无双折射现象,保持共聚物液晶性的最低含介晶基元单体的极限摩尔含量为80%.在液晶共聚物中,非介晶基组分含量增加时,其T_m、ΔH_m和ΔS_m降低;非介晶组分在10mol%时,T_i、ΔH_i和ΔS_i具有最小值。     

(±)-3-正丁基-4-甲氧基苯酞的合成

以3-羟基苯甲酸为原料,通过中间体(±)-3-羟基-4-甲氧基苯酞合成了(±)-3-正丁基-4-甲氧基苯酞(?)。     

聚(4-三甲基硅基)苯乙炔膜的气体透过性

合成了4-三甲基硅基苯乙炔(SPA)单体,采用核磁共振谱(1H-NMR)和傅里叶变换红外光谱(FT-IR)对其进行了表征.在Pd(PPh3)2Cl2和金属共催化剂催化下制备了聚4-三甲基硅基苯乙炔(PSPA).PSPA易溶于氯仿、甲苯等有机溶剂,成膜性较好,具有较高的强度和热稳定性.热重分析(TGA)表明其5%失重温度为300～310℃.PSPA膜对CO2气体透过系数达到848 Barrer,并具有较高的透过选择性,分离系数达到12.68,摆脱了"Robeson"上限的限制.     

1,4-双(取代苯乙炔基)苯及反,反-1,4-双(β-取代苯乙烯基)苯的电子光谱的研究

测定了1,4-双(取代苯乙炔基)苯(Ⅰ)和反,反-1,4-双(β-取代苯乙烯基)苯(Ⅱ)的紫外光谱、荧光光谱.用CNDO/S-CI和HMO方法对苯乙炔、二苯乙炔和(Ⅰ)及苯乙烯、1,2-二苯乙烯和(Ⅱ)的激发能进行了计算和研究.讨论了化合物结构对光谱的影响.     

α-(2-噻唑基脲基)膦酸二苯酯的合成

报道了一种简便的合成取代脲基膦酸酯的通用的新方法。在二氯甲烷中,三乙胺为缚酸剂的条件下,α-氨基膦酸二苯酯与三聚光气反应形成α-异氰酸基膦酸酯2,2不经分离,直接与2-氨基(苯并)噻唑加成得到α-(2-噻唑基脲基)膦酸二苯酯3,产率55.0%-88.9%。     

2-甲氧基-4-吗啉基重氮苯氯化锌盐的结构鉴定

通过红外光谱(IR)、能谱(EDS)、液质联用(LC-MS)以及核磁共振(NMR)等现代仪器分析技术,对一种黄色未知物进行结构鉴定,确认未知物的结构为2-甲氧基-4-吗啉基重氮苯氯化锌盐。     

2,5-二(2-羟乙氨基)-1,4-苯醌合成方法的改进

以对苯二酚和乙醇胺为原料,直接合成2,5-二(2-羟乙氨基)-1,4-苯醌,并对产物进行红外、紫外、质谱及核磁表征.采用正交设计法对实验条件进行优化,乙醇为溶剂,对苯二酚和乙醇胺物质的量比为1∶5,在50℃下,反应2h,最高产率达到72.8%.产物为针状晶体,纯度较高.     

1,3,5-三[(4’-乙炔基苯基)乙炔基]苯的合成

设计了多种合成路线制备芳香炔基树枝状化合物中间体1,3,5-三[(4’-乙炔基苯基)乙炔基]苯,通过一系列的合成路线和反应条件的对比,发现多官能团的端基炔化合物与芳基溴化合物之间发生多重Sonogashira反应时,常会生成不同取代程度的极性相似化合物,因而难以分离.采用多官能团的端基炔化合物与芳基碘化合物反应可以避免这种情况.最终确定以1,3,5-三溴苯和2-甲基-3-丁炔-2-醇为原料,制得中间产物1,3,5-三乙炔基苯;再以对碘苯胺和三甲基硅乙炔为原料,经重氮化化、卤代反应制得4-三甲基硅乙炔基碘苯;后者与1,3,5-三乙炔苯经Sonogashira反应、裂解去保护反应,制得化合物1,3,5-三[(4’-乙炔基苯基)乙炔基]苯.用1H NMR,13C NMR,元素分析等表征手段确认了中间体及最终产物的结构.     

Synthesis of 2-Aryl and 2-Hetaryl Derivatives of 2'-Aminospiro[(1,3-dioxane)-5,5'-thiazolin]-4'-one and Spiro[(1,3-dioxane)-5,5'-thiazolidine]2',4'-dione

2-(Het)aryl derivatives of 2'-aminospiro[(1,3-dioxane)-5,5'-thiazolin]-4'-one or spiro[(1,3-dioxane)-5,5'-thiazolidine]-2',4'-dione are formed by the acid catalyzed interaction of 2-amino-5,5-bis(hydroxymethyl)-4-thiazolinone or its oxo analog 5,5-bis(hydroxymethyl)thiazolidine-2,4-dione with (hetero)aromatic aldehydes.     

2-[1-(4-甲酰氨基苯基乙酰氧)烷基]-1,4-二羟基-9,10-蒽醌类衍生物的 合成及其抗肿瘤作用研究

为寻找抗肿瘤作用强、毒性低并且对癌细胞具有靶向性的新蒽醌类化合物, 合成了未见报道的12个2-[1-(4-甲酰氨苯基乙酰氧)烷基]-1,4-二羟基-9,10-蒽醌类衍生物, 分别用L1210癌细胞进行细胞毒性实验及小鼠S180腹水癌做了体内抗肿瘤实验. 实验结果表明, 蒽醌侧链中引入对甲酰氨基苯乙酰基后细胞毒性增强. 随着侧链碳链数的增加细胞毒性随之逐渐减小, 当烷基侧链中的碳数超过7以上时, 细胞毒性消失. 当侧链R基为苯环时与脂肪烃链或环己基相比细胞毒性更大, 说明芳香环对癌细胞具有更强的抑制作用. S180小鼠抗肿瘤实验结果表明, 蒽醌侧链中引入对甲酰氨基苯甲酰基后活性无显著性变化.     

Resonance Rayleigh scattering spectra of ion-association nanoparticles of [Co(4-[(5-Chloro-2-pyridyl) azo]-1, 3-diaminobenzene)2]-sodium dodecyl benzene sulfonate system and its analytical application

In pH 1.8-3.0 Britton-Robinson (BR) buffer solution, cobalt (II) reacts with 4-[(5-Chloro-2-pyridyl) azo]-1, 3-diaminobenzene (5-Cl-PADAB, L) to form a cationic chelate [CoL₂]²⁺. When interacting with anionic surfactants (AS) such as sodium dodecyl benzene sulfonate (SDBS), sodium dodecyl sulfate (SDS) or sodium dodecyl sulfonate (SLS), the chelate can only react with SDBS to form ternary ion-association complexes ([CoL₂][SDBS]₂). By virtue of the extrusion action of water and Van der Waals force, the hydrophobic ion-association complexes draw close to each other and further aggregate to form {[CoL₂][SDBS]₂}_n nanoparticles with an average diameter of 30 nm. As a result, resonance Rayleigh scattering (RRS) is enhanced greatly and new RRS spectra appear. Under the same conditions, both SDS and SLS exhibit no similar reactions and do not result in obvious change of RRS. Therefore, SDBS can be determined selectively by RRS method in the presence of SDS or SLS. The wavelength of 516 nm was chosen as a detection wavelength, the linear range and the detection limit (3σ) are 0.05-6.0 μg mL⁻¹ and 0.015 μg mL⁻¹ for the determination of SDBS, respectively. The characteristics of RRS spectra of the [CoL₂]²⁺-SDBS system, the optimum conditions of the reaction and the influencing factors have been investigated. The effects of coexisting substances have been examined too, indicating a good selectivity of the method for the determination of SDBS. The method can be used for the determination of SDBS in waste water and river water samples, and the results are satisfactory compared with those of standard samples of SDBS. Based on the formation of {[CoL₂][SDBS]₂}_n nanoparticles, a sensitive, simple and rapid method has been developed for the determination of SDBS in environmental water samples using a RRS technique. Moreover, the reaction mechanism was discussed.     

N，N，N’，N’-四[（二苯基膦）亚甲基]-对苯二胺的合成及其晶体结构

有机膦化合物具有的广泛用途,如在农业上可作为杀虫剂、杀菌剂、除草剂[1],在工业上作为抗氧剂、助燃剂、粘接剂、缓蚀剂等[2],使得有机膦化学飞速发展,有机膦化合物的应用日益丰富[3,4].     

Synthesis and Crystal Structure of Tert-butyl 4-[(E)-4-(1,3 -Dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-butenyl] Benzoate

1 INTRODUCTION Phthalimide and its derivatives are synthetic mate- rials, which are widely used as important chemical intermediates of biosensors[1] and many drugs such as Citalopran[2], luminal[3], Beta-Lactam[4] and the No. three generation quinolones[5], and they have been identified as active groups of some drugs and chemical luminescence reagents[6, 7]. Tert-butyl 4- [(E)-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1- butenyl] benzoate is an intermediate of a new type of insulin sen…     

1-[(乙氧基)甲基]-6-(1-萘甲基)胸腺嘧啶的合成

HEPT是抑制HIV-1逆转录酶的潜在活性化合物。1-[(乙氧基)甲基]-6-(1-萘甲基)胸腺嘧啶是HEPT的类似物,通过增加6位取代基的位阻可提高药效。文献设计并合成了该化合物,并对关键中间体(d)的合成及脱羟基反应作了初步讨论。     

1,5-Dimethy-4-[(3-nitro-benzylidene)-amino]-2-pheyl-1,2-dihydro-pyrazol-3-one

1INTRODUCTION Antipyrine(2,3-dimethyl-1-phenyl-5-pyrazolone)and its derivatives exhibit a wide range of biological activities and applications[1~3].Antipyrine shows mi-nimal protein binding and is rapidly and completely absorbed from the gastrointestinal tract and exten-sively metabolized by the cytochrome P450liver en-zymes[4].Estimates of half-life and systemic cleara-nce of antipyrine have been used for the in vivo asse-ssment of hepatic drug oxidation in different spe-cies[5].Owing to…     

A practical synthesis of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid—the key precursor toward imatinib

A simple and efficient in situ synthesis of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid through direct reductive alkylation of 1-methylpiperazine in the presence of triacetoxy sodium borohydride in 95-99% yields is elaborated. The process is easy to scale-up for the large-scale synthesis of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid as the key synthetic intermediate of imatinib. This method was used for the synthesis of benzyl derivatives of heterocyclic amines in 87-90% yields.